Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

What happened: Ascletis announced positive preclinical data for its once-weekly oral peptide pipeline for obesity, including ASC36o, an amylin receptor peptide agonist now in a U.S. Phase I study. Key numbers: ASC36o half-life up to 167 hours (about 7 days) and oral bioavailability of 6% to 8% in non-human primates. Why it matters: Ascletis states the pipeline covers all four validated targets and that its two fixed-dose combinations are, to its knowledge, the first once-weekly oral peptide FDCs, which it believes gives it the most comprehensive pipeline in the industry.

Ascletis announced positive preclinical data for its once-weekly oral peptide pipeline for obesity, including ASC36o, an amylin receptor peptide agonist now in a U.S. Phase I study.

Ascletis states the pipeline covers all four validated targets and that its two fixed-dose combinations are, to its knowledge, the first once-weekly oral peptide FDCs, which it believes gives it the most comprehensive pipeline in the industry.